Investment Analysts’ updated eps estimates for Tuesday, January 21st:
Apple (NASDAQ:AAPL) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $260.00 price target on the stock.
Abbott Laboratories (NYSE:ABT) had its outperform rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $135.00 price target on the stock.
AudioEye (NASDAQ:AEYE) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $25.00 target price on the stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $300.00 target price on the stock.
Amazon.com (NASDAQ:AMZN) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $250.00 target price on the stock.
Apellis Pharmaceuticals (NASDAQ:APLS) had its sector perform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $26.00 price target on the stock.
AudioCodes (NASDAQ:AUDC) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $11.00 price target on the stock.
Anavex Life Sciences (NASDAQ:AVXL) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $42.00 target price on the stock.
Axos Financial (NYSE:AX) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $85.00 price target on the stock.
Axsome Therapeutics (NASDAQ:AXSM) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $180.00 price target on the stock.
BOK Financial (NASDAQ:BOKF) had its equal weight rating reiterated by analysts at Stephens. Stephens currently has a $135.00 price target on the stock.
Citizens Financial Group (NYSE:CFG) had its overweight rating reiterated by analysts at Stephens. Stephens currently has a $53.00 target price on the stock.
Citizens Financial Group (NYSE:CFG) had its strong-buy rating reiterated by analysts at Raymond James. The firm currently has a $58.00 target price on the stock, up from their previous target price of $55.00.
Cipher Mining (NASDAQ:CIFR) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $7.50 price target on the stock.
Coya Therapeutics (NASDAQ:COYA) had its buy rating reiterated by analysts at D. Boral Capital. D. Boral Capital currently has a $15.00 target price on the stock.
Emergent BioSolutions (NYSE:EBS) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $15.00 price target on the stock.
89bio (NASDAQ:ETNB) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $29.00 price target on the stock.
Five9 (NASDAQ:FIVN) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $52.00 target price on the stock.
Huntington Bancshares (NASDAQ:HBAN) had its equal weight rating reaffirmed by analysts at Stephens. They currently have a $18.50 target price on the stock.
Huntington Bancshares (NASDAQ:HBAN) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $20.00 target price on the stock.
Humacyte (NASDAQ:HUMA) had its buy rating reissued by analysts at D. Boral Capital. They currently have a $25.00 price target on the stock.
Independent Bank (NASDAQ:INDB) had its strong-buy rating reissued by analysts at Raymond James. The firm currently has a $78.00 target price on the stock, up from their previous target price of $74.00.
iRobot (NASDAQ:IRBT) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Disc Medicine (NASDAQ:IRON) had its outperform rating reaffirmed by analysts at Wedbush. The firm currently has a $90.00 target price on the stock, up from their previous target price of $83.00.
Jamf (NASDAQ:JAMF) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $25.00 target price on the stock.
KB Home (NYSE:KBH) had its outperform rating reiterated by analysts at Raymond James. They currently have a $80.00 price target on the stock, down from their previous price target of $93.00.
Kymera Therapeutics (NASDAQ:KYMR) had its overweight rating reaffirmed by analysts at Stephens. They currently have a $60.00 target price on the stock.
Legend Biotech (NASDAQ:LEGN) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $73.00 price target on the stock.
Lantronix (NASDAQ:LTRX) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $5.50 target price on the stock.
Lexeo Therapeutics (NASDAQ:LXEO) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $24.00 price target on the stock.
Neogen (NASDAQ:NEOG) had its neutral rating reaffirmed by analysts at Piper Sandler. They currently have a $13.00 target price on the stock, down from their previous target price of $16.50.
Nurix Therapeutics (NASDAQ:NRIX) had its overweight rating reaffirmed by analysts at Stephens. The firm currently has a $31.00 price target on the stock.
Nutrien (NYSE:NTR) had its equal weight rating reaffirmed by analysts at Barclays PLC. The firm currently has a $56.00 target price on the stock, up from their previous target price of $55.00.
Grupo Aeroportuario del Pacífico (NYSE:PAC) had its equal weight rating reiterated by analysts at Barclays PLC.
Private Bancorp of America (OTCMKTS:PBAM) had its overweight rating reaffirmed by analysts at Piper Sandler. The firm currently has a $78.00 price target on the stock, down from their previous price target of $80.00.
Perion Network (NASDAQ:PERI) had its hold rating reiterated by analysts at Needham & Company LLC.
Polaris (NYSE:PII) had its equal weight rating reiterated by analysts at Morgan Stanley. Morgan Stanley currently has a $60.00 target price on the stock, down from their previous target price of $81.00.
Planet Fitness (NYSE:PLNT) had its neutral rating reissued by analysts at DA Davidson. They currently have a $87.00 target price on the stock.
uniQure (NASDAQ:QURE) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $24.00 price target on the stock.
REGENXBIO (NASDAQ:RGNX) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $30.00 target price on the stock.
Avidity Biosciences (NASDAQ:RNA) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $67.00 price target on the stock.
Ross Stores (NASDAQ:ROST) had its equal weight rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $140.00 price target on the stock, down from their previous price target of $164.00.
Reviva Pharmaceuticals (NASDAQ:RVPH) had its buy rating reiterated by analysts at D. Boral Capital. D. Boral Capital currently has a $15.00 target price on the stock.
Schlumberger (NYSE:SLB) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $57.00 price target on the stock.
Summit Therapeutics (NASDAQ:SMMT) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $44.00 price target on the stock.
Strategic Education (NASDAQ:STRA) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $135.00 price target on the stock.
Symbotic (NASDAQ:SYM) had its sell rating reiterated by analysts at BWS Financial. BWS Financial currently has a $10.00 target price on the stock.
Talphera (NASDAQ:TLPH) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $6.00 target price on the stock.
Tapestry (NYSE:TPR) had its equal weight rating reaffirmed by analysts at Morgan Stanley. They currently have a $65.00 price target on the stock.
TechTarget (NASDAQ:TTGT) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $18.00 target price on the stock.
Twilio (NYSE:TWLO) had its underperform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $50.00 price target on the stock.
Texas Instruments (NASDAQ:TXN) had its buy rating reissued by analysts at Rosenblatt Securities. They currently have a $250.00 price target on the stock.
Tyler Technologies (NYSE:TYL) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $700.00 price target on the stock.
Vanda Pharmaceuticals (NASDAQ:VNDA) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $18.00 price target on the stock.
Verona Pharma (NASDAQ:VRNA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $60.00 price target on the stock, up from their previous price target of $42.00.
Viasat (NASDAQ:VSAT) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $19.00 price target on the stock.
Valvoline (NYSE:VVV) had its equal weight rating reiterated by analysts at Morgan Stanley. The firm currently has a $38.00 price target on the stock, down from their previous price target of $42.00.
Wendy’s (NASDAQ:WEN) had its underweight rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $14.00 target price on the stock, down from their previous target price of $22.00.
Yum! Brands (NYSE:YUM) had its equal weight rating reiterated by analysts at Morgan Stanley. Morgan Stanley currently has a $140.00 price target on the stock, down from their previous price target of $158.00.
Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.
